Neurofibromas are benign tumors that are made up of multiple cells like Schwann cells, fibroblasts, mast cells, perineural cells, macrophages, and T cells. They can occur in the skin, soft tissue, and nerves and roughly present as solitary lesions in 90% of cases. Multiple neurofibromas may be part of syndromes like neurofibromatosis-1 or NF-1 and they need to be managed accordingly. Usually the general treatment approach for neurofibromas has been observation until they are symptomatic or can potentially lead to severe damage or cosmetic disturbances. The most common treatment for neurofibromas has been surgery where feasible. However, recently there have been few case reports on the use of radiation in neurofibromas. The main reason behind limited use has been the side effects associated with conventional radiation techniques used historically. However, with newer techniques like three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy, side effects to normal tissue can be avoided allowing radiation treatment to stand as a valid alternative option. Another new advance has been research into the molecular background of neurofibromas leading to the use of newer drugs like MEK inhibitors which seem to have a promising future. One of the reasons for renewed interest in radiotherapy has been the advancements in technology which can help in controlling the disease in a noninvasive manner with lesser morbidity as compared to surgery in certain conditions. A lot more research needs to be done to find the optimum treatment approach for management of neurofibromas.